RxDoctor Payments Data

David Gill, DO

Neurology · Saginaw, MINPI 1447562236

Payments from drug & device makers

$5,052in general payments, 2019–2025

Across 300 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Biogen$328
  • UCB, Inc.$231
  • Pfizer$193
  • Lilly USA, LLC$177
  • Bristol Myers Squibb$174
  • plus $2K from 39 others

What the payments were for

  • Speaking & faculty fees$842%
  • Food & beverage$4,95198%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,052 in reported general payments places this provider in the 65th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$69,587
Medicare patients
339
Services billed
1,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Plegridy PenPeginterferon Beta-1a14$113,700
VumerityDiroximel Fumarate12$101,452
Nurtec OdtRimegepant Sulfate80$93,512
BriviactBrivaracetam44$86,399
AptiomEslicarbazepine Acetate25$46,374
Aimovig AutoinjectorErenumab-Aooe43$41,795
QuliptaAtogepant29$32,536
NuedextaDextromethorphan Hbr/Quinidine25$27,435
Emgality PenGalcanezumab-Gnlm31$23,740
Lacosamide105$21,049
Teriflunomide11$20,160
Emgality SyringeGalcanezumab-Gnlm11$18,889
Dimethyl Fumarate39$17,848
UbrelvyUbrogepant16$16,261
Levetiracetam249$9,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$328$101,45212 claims
PfizerNurtec Odt$193$93,51280 claims
UCB, Inc.Briviact$231$86,39944 claims
AbbVieQulipta, Ubrelvy$1,513$48,79745 claims
Sunovion Pharmaceuticals Inc.Aptiom$75$46,37425 claims
Avanir Pharmaceuticals, Inc.Nuedexta$42$27,43525 claims
Neurelis, Inc.Valtoco$64$8,53812 claims
Upsher-smith Laboratories LLCTopiramate$50$3,303183 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$30$2,42838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 652 neurology providers in Michigan.

Other neurology in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →